Skip to main content

Table 1 Demographic, clinical and laboratory characteristics for patients at baseline and at the 3-month visit (time for randomisation)

From: Infliximab therapy increases body fat mass in early rheumatoid arthritis independently of changes in disease activity and levels of leptin and adiponectin: a randomised study over 21 months

 

Treatment A (n= 22)

Treatment B (n= 18)

Baseline

  

   Age (years)

59.5 (58.0 to 67.0)

56.0 (42.0 to 73.0)

   Women

16 (73%)

13 (72%)

   Menopause

14 (88%)

8 (62%)

   Current or previous smoker

15(68%)

7 (41%)

   Disease duration (months)

5.4 (2.9)

4.9 (3.4)

   Rheumatoid factor positivity

11 (50%)

10 (56%)

   X-ray criteria at baseline

7 (32%)

2 (11%)

3-month visit

  

   Erythrocyte sedimentation rate (mm)

25.0 (14.0 to 29.0)

23.5 (12.0 to 34.0)

   Disease Activity Score of 28 joints

4.3 (4.1 to 4.9)

4.8 (3.7 to 5.1)

   HAQ score

0.86 (0.50)

0.89 (0.18)

   Leptin (μg/l)

8.8 (5.4 to 27.7)

7.9 (3.9 to 14.2)

   Adiponectin (mg/l)

10.7 (3.4)

10.9 (6.6)

   Apolipoprotein A1 (g/l)

1.46 (0.25)

1.64 (0.23)

   Apolipoprotein B (g/l)

1.10 (0.26)

1.03 (0.21)

   Apolipoprotein B/apolipoprotein A1

0.77 (0.24)

0.64 (0.15)

   P1NP (μg/l)

46 (36 to 58)

43 (32 to 68)

   CTX-1 (pg/ml)

280 (191 to 368)

233 (119 to 457)

   1CTP (μg/l)

4.1 (3.3 to 5.6)

3.7 (2.9 to 4.9)

   IGF-1 (μg/l)

145.5 (114.0 to 166.0)

154.5 (130.0 to 193.0)

   IGF-1 SD scores

-0.09 (1.34)

-0.07 (-0.12)

  1. Demographic, clinical and laboratory characteristics at baseline and at the 3-month visit (time for randomisation). Data presented as median (interquartile range), n (%) or mean (standard deviation (SD)). Treatment A, methotrexate + sulphasalazine + hydroxychloroquine; treatment B, methotrexate + infliximab. HAQ, Health Assessment Questionnaire, P1NP, procollagen type I N-terminal propeptide; CTX-1, C-terminal telopeptide of type I collagen; 1CTP, C-terminal propeptide of type I collagen; IGF-1, insulin-like growth factor-1.